Garadacimab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and G-BA (Germany), among others, recommended or restricted garadacimab, while NYE METODER (Norway) did not recommend it.
Every record falls within a 1.5-year window, 2024 to 28 Jan 2026 — a compressed review cycle.
No assessment is on file from HAS (France) and SMC (Scotland), each among the eight highest-volume agencies here.
The file is active: 9 of 10 records date from 2023 or later.
3 distinct indication wordings are recorded for garadacimab by the agencies that label one in English (AWMSG, NICE and PBAC).
1 of these 10 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
PBAC (Australia) was first to assess garadacimab, in 2024; CIPM (Spain) did not open a file until 28 Jan 2026 — a moderate spread of 1.5 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 9 dated records fall in 2025 alone.
10 of the 18 agencies in this archive hold a record for garadacimab.
The full ledger for garadacimab reads 6 recommended, 1 restricted, 1 not recommended and 1 appraised, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| TLV (Sweden) | 27 Jan 2026 | Andembry ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| NYE METODER (Norway) | 7 Dec 2025 | For rutinemessig forebygging av residiverende anfall av hereditært angioødem (HAE) hos pasienter ≥12 år | not introduced | source |
| DMC (Denmark) | 29 Oct 2025 | Til rutinemæssig forebyggelse af tilbagevendende anfald af hereditært angioødem (HAE) hos voksne og unge patienter i ald… | Direkte indplacering | source |
| NICE (England) | 8 Oct 2025 | NICE TA1101 | published appraisal | source |
| ZIN (Netherlands) | 26 Aug 2025 | Advies - vergoed garadacimab (Andembry®) voor de behandeling van hereditair angio-oedeem (HAE) | reimbursed | source |
5 further decisions for garadacimab, across 5 agencies, are not shown here. They include the most recent record on file, 28 Jan 2026 from CIPM (Spain); its outcome is in the subscriber dataset. They link to 5 further source documents.
Related molecules
- lanadelumab — same ATC class B06A — Other hematological agents
- exagamglogene autotemcel — same ATC class B06A — Other hematological agents
- icatibant — same ATC class B06A — Other hematological agents
- berotralstat — same ATC class B06A — Other hematological agents
- conestat alfa — same ATC class B06A — Other hematological agents
- donidalorsen — same ATC class B06A — Other hematological agents
Coverage: 10 decisions for garadacimab from 10 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class B06A — Other hematological agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.